Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Alzamend Neuro, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 16 | 1 | 12 | −3 |
| SharesConverted for a 1-for-10 split | 38.0K | 3.97K | 42.1K | +8.07K (+23.7%) |
| Value | $150.5K | $15.7K | $71.2K | −$63.6K (−47.2%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held Alzamend Neuro, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 16,601 | $28.1K | 0.00% |
| BlackRock, Inc. | 3,973 | $6.71K | 0.00% |
| Wells Fargo & Company | 1,000 | $1.69K | 0.00% |
Sold out (6)
Institutions that held Alzamend Neuro, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Vanguard Group Inc | 78,545 | $31.0K |
| Geode Capital Management, LLC | 52,397 | $21.2K |
| Renaissance Technologies LLC | 19,690 | $7.77K |
| RFG Advisory, LLC | 16,666 | $6.57K |
| UBS Group AG | 5,132 | $2.02K |
| Advisor Group Holdings, Inc. | 66 | $26 |
Not filed for Q3 2024 yet (1)
Institutions that held Alzamend Neuro, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 39,740 | $15.7K |